The Federal Institute of Intellectual Property can also issue a supplementary protection certificate to an applicant if a certificate for the same active pharmaceutical ingredients (API) or combination thereof has already been granted to a third person. By interpreting the law in that way – only restricting the grant of a certificate for the same API to the same applicant- Swiss law is harmonized with the current jurisprudence of the EU.

Click here for the full text of this case.

A full summary of this case has been published on Kluwer IP Law.

image_pdfimage_print

Leave a Reply

Your email address will not be published. Required fields are marked *